Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast?
- 1 May 2000
- journal article
- review article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 55 (2), 95-99
- https://doi.org/10.1016/s0167-8140(99)00186-3
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomasBritish Journal of Cancer, 1997
- Consensus conference on the classification of ductal carcinoma in SituCancer, 1997
- Amplification units and translocation at chromosome 17q and c- erb B-2 overexpression in the pathogenesis of breast cancerVirchows Archiv, 1997
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- Extensive apoptosis in ductal carcinoma in situ of the breastCancer, 1996
- Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B-17. Intraductal carcinoma (ductal carcinoma in situ)Cancer, 1995
- Apoptosis in cancer therapy: Crossing the thresholdCell, 1994
- Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast CancerNew England Journal of Medicine, 1993
- Breast CancerNew England Journal of Medicine, 1992
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992